William Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases
Genzyme has appointed leaders for its core multiple sclerosis and rare diseases businesses.
William “Bill” Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases.
“These appointments are a critical step in launching the new Genzyme,” said the company's CEO David Meeker. “Bill and Rogério are dynamic leaders with the experience, energy, vision and commitment to patients needed to move us forward.”
Sibold has more than 20 years of experience in the biopharmaceutical industry, including eight years at Biogen Idec where he worked on multiple sclerosis products Avonex and Tysabri.
He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.
Vivaldi has been with Genzyme since 1997 and was most recently president of Genzyme's renal and endocrinology business. He previously served as senior vice president and president of Genzyme Latin America.